Guangzhou Baiyunshan Pharmaceutical Holdings (00874) reported that operating income in the third quarter of 2025 reached approximately RMB19.77 billion, a 9.74% increase compared with the same period last year. Net profit attributable to shareholders stood at around RMB793.91 million, registering a 30.28% year-on-year rise.

From January to September 2025, the Company achieved operating income of roughly RMB61.61 billion, up 4.31% from the prior year’s corresponding period. Net profit attributable to shareholders totaled about RMB3.31 billion during the nine months, reflecting a 4.78% increase. Meanwhile, total assets reached RMB83.17 billion as of 30 September 2025, 1.82% higher than at the end of 2024, and total equity attributable to shareholders rose by 5.58% to RMB37.91 billion.

The Company’s net cash flow from operating activities was negative RMB1.97 billion for the first three quarters, attributed to a decrease in payment collection by subsidiaries and higher procurement-related payments. Non-recurring items during the reporting period contributed RMB130.08 million in the third quarter, mainly from subsidy income and fair value changes. The Board of Directors has confirmed the authenticity and completeness of these figures as reported.